NO971520L - Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y - Google Patents
Fremgangsmåte for hemming av tilstander forbundet med neuropeptid YInfo
- Publication number
- NO971520L NO971520L NO971520A NO971520A NO971520L NO 971520 L NO971520 L NO 971520L NO 971520 A NO971520 A NO 971520A NO 971520 A NO971520 A NO 971520A NO 971520 L NO971520 L NO 971520L
- Authority
- NO
- Norway
- Prior art keywords
- neuropeptide
- conditions associated
- inhibiting conditions
- inhibiting
- hexamethylenimino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/326,675 US6562862B1 (en) | 1994-10-20 | 1994-10-20 | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
PCT/US1995/013246 WO1996012490A1 (en) | 1994-10-20 | 1995-10-19 | Methods of inhibiting conditions associated with neuropeptide y |
Publications (2)
Publication Number | Publication Date |
---|---|
NO971520D0 NO971520D0 (no) | 1997-04-03 |
NO971520L true NO971520L (no) | 1997-04-03 |
Family
ID=23273204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO971520A NO971520L (no) | 1994-10-20 | 1997-04-03 | Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y |
Country Status (19)
Country | Link |
---|---|
US (5) | US6562862B1 (sv) |
EP (1) | EP0785785A4 (sv) |
JP (1) | JPH10507757A (sv) |
KR (1) | KR970706818A (sv) |
CN (1) | CN1091598C (sv) |
AU (1) | AU689664B2 (sv) |
CA (1) | CA2200990A1 (sv) |
CZ (1) | CZ287411B6 (sv) |
FI (1) | FI971635A0 (sv) |
HU (1) | HUT76852A (sv) |
IL (1) | IL115663A (sv) |
MY (1) | MY132056A (sv) |
NO (1) | NO971520L (sv) |
NZ (1) | NZ295575A (sv) |
RU (1) | RU2188015C2 (sv) |
TW (1) | TW410156B (sv) |
UA (1) | UA46744C2 (sv) |
WO (1) | WO1996012490A1 (sv) |
ZA (1) | ZA958800B (sv) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5989920A (en) * | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
US5494929A (en) * | 1995-01-12 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting growth hormone effects |
US5840747A (en) * | 1995-06-07 | 1998-11-24 | Eli Lilly And Company | Calcium channel antagonists |
US5532254A (en) * | 1995-06-07 | 1996-07-02 | Eli Lilly And Company | Modulation of calcium channels using benzothiophenes |
EP0759441A3 (en) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Methods of treating neuropeptide Y-associated conditions |
US5972624A (en) * | 1996-01-24 | 1999-10-26 | Synaptic Pharmaceutical Corporation | Method of identifying ligands which bind recombinant galanin receptor (GALR2) |
AU730137B2 (en) * | 1996-01-24 | 2001-03-01 | H. Lundbeck A/S | DNA encoding galanin GALR2 receptors and uses thereof |
WO1997026876A1 (en) * | 1996-01-29 | 1997-07-31 | Eli Lilly And Company | Methods of increasing sphincter competence |
US6113876A (en) * | 1996-01-29 | 2000-09-05 | Eli Lilly And Company | Methods of increasing sphincter competence |
WO1998007420A1 (en) | 1996-08-23 | 1998-02-26 | Agouron Acquisition Corp. | Neuropeptide-y ligands |
US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
CA2251368A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
US6048900A (en) * | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
JP2000510870A (ja) * | 1997-02-14 | 2000-08-22 | バイエル・コーポレーシヨン | Npy5受容体アンタゴニストとしてのアミド類 |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
DE69812096T2 (de) * | 1997-04-23 | 2003-10-30 | Banyu Pharmaceutical Co., Ltd. | Neuropeptid y rezeptorantagonisten |
US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
DE69830409T2 (de) | 1997-08-05 | 2006-01-26 | Pfizer Products Inc., Groton | 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten |
PT896822E (pt) * | 1997-08-05 | 2003-07-31 | Pfizer Prod Inc | 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y |
US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
WO1999008523A1 (en) * | 1997-08-21 | 1999-02-25 | Eli Lilly And Company | Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis |
WO1999008526A1 (en) * | 1997-08-21 | 1999-02-25 | Eli Lilly And Company | Methods for inhibiting temporomandibular disorders |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US20050107327A1 (en) * | 1997-12-19 | 2005-05-19 | Hormos Medical Corporation | Method for reducing overproduction of neuropeptide Y in an individual |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
GB2344050A (en) * | 1998-11-26 | 2000-05-31 | Ferring Bv | Agents useful in the treatment of reproductive disorders. |
EP1027891B1 (en) | 1999-01-27 | 2004-12-29 | Pfizer Products Inc. | Neuropeptide y antagonists |
KR20010101931A (ko) | 1999-02-03 | 2001-11-15 | 피터 지. 스트링거 | α1-아드레날린성 수용체 길항제 |
DE19905961A1 (de) * | 1999-02-12 | 2000-08-17 | Stefan Neubauer | Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz |
US6489308B1 (en) * | 1999-03-05 | 2002-12-03 | Trustees Of University Of Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions |
AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
CA2379640C (en) | 1999-09-30 | 2006-11-28 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
WO2001053477A1 (en) * | 2000-01-20 | 2001-07-26 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
JP2001261674A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6511984B2 (en) | 2000-03-30 | 2003-01-28 | Pfizer Inc. | Neuropeptide Y antagonists |
US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
AU2001273144A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
WO2003049673A2 (en) | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
US6958347B2 (en) * | 2002-12-18 | 2005-10-25 | Pfizer Inc. | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists |
US6949564B2 (en) * | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
JP2004224756A (ja) * | 2003-01-24 | 2004-08-12 | Sumika Fine Chemicals Co Ltd | 2,6−ジハロゲノ−8−置換−プリン化合物およびその製造方法 |
US20040220242A1 (en) * | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
US7371871B2 (en) | 2003-05-05 | 2008-05-13 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
CA2544573A1 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
CA2554809C (en) | 2004-02-05 | 2014-04-29 | Probiodrug Ag | Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase |
US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
ES2391626T3 (es) | 2004-05-04 | 2012-11-28 | Hormos Medical Ltd. | Nuevas composiciones orales de ospemifeno |
WO2006050999A2 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
ES2590262T3 (es) * | 2007-02-14 | 2016-11-21 | Hormos Medical Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
SI2225261T1 (sl) | 2007-12-03 | 2016-07-29 | Obe Therapy Biotechnology | Boropeptidni inhibitorji enteropeptidaze in njihove uporabe pri zdravljenju debelosti, prekomerne teže in/ali bolezni, povezanih z nenormalno presnovo maščob |
ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤 |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
MY174888A (en) * | 2013-02-19 | 2020-05-20 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4891357A (en) * | 1985-02-11 | 1990-01-02 | University Of Florida | Methods and compositions for stimulation of appetite |
US5075321A (en) | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
AU672182B2 (en) | 1991-11-27 | 1996-09-26 | Novo Nordisk A/S | Piperidine derivatives and their use in treating psychosis |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
DE4311870C2 (de) | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5445941A (en) | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
CZ285522B6 (cs) | 1993-06-24 | 1999-08-11 | Eli Lilly And Company | Farmaceutický prostředek pro snížení koncentrace glukosy v krvi |
TW303299B (sv) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US5457113A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5476862A (en) | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
US5578613A (en) | 1993-12-21 | 1996-11-26 | Eli Lilly And Company | Methods for inhibiting weight gain or inducing weight loss |
US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
JPH07196494A (ja) | 1993-12-21 | 1995-08-01 | Eli Lilly & Co | 強迫性障害および消費性障害を抑制するための医薬組成物 |
US5574047A (en) | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5439931A (en) * | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
-
1994
- 1994-10-20 US US08/326,675 patent/US6562862B1/en not_active Expired - Fee Related
-
1995
- 1995-08-21 US US08/517,316 patent/US5576337A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,303 patent/US5504094A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,049 patent/US5567714A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,315 patent/US5567715A/en not_active Expired - Fee Related
- 1995-10-18 IL IL11566395A patent/IL115663A/xx not_active IP Right Cessation
- 1995-10-18 ZA ZA958800A patent/ZA958800B/xx unknown
- 1995-10-18 TW TW084110967A patent/TW410156B/zh not_active IP Right Cessation
- 1995-10-19 MY MYPI95003138A patent/MY132056A/en unknown
- 1995-10-19 WO PCT/US1995/013246 patent/WO1996012490A1/en not_active Application Discontinuation
- 1995-10-19 EP EP95938248A patent/EP0785785A4/en not_active Withdrawn
- 1995-10-19 CN CN95195703A patent/CN1091598C/zh not_active Expired - Fee Related
- 1995-10-19 JP JP8514008A patent/JPH10507757A/ja active Pending
- 1995-10-19 UA UA97041869A patent/UA46744C2/uk unknown
- 1995-10-19 RU RU97108050/14A patent/RU2188015C2/ru active
- 1995-10-19 KR KR1019970702591A patent/KR970706818A/ko not_active Application Discontinuation
- 1995-10-19 CA CA002200990A patent/CA2200990A1/en not_active Abandoned
- 1995-10-19 HU HU9701520A patent/HUT76852A/hu unknown
- 1995-10-19 CZ CZ19971159A patent/CZ287411B6/cs not_active IP Right Cessation
- 1995-10-19 AU AU38955/95A patent/AU689664B2/en not_active Ceased
-
1997
- 1997-04-03 NO NO971520A patent/NO971520L/no not_active Application Discontinuation
- 1997-04-17 FI FI971635A patent/FI971635A0/sv unknown
- 1997-04-17 NZ NZ295575A patent/NZ295575A/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA46744C2 (uk) | 2002-06-17 |
FI971635A (sv) | 1997-04-17 |
US6562862B1 (en) | 2003-05-13 |
CA2200990A1 (en) | 1996-05-02 |
WO1996012490A1 (en) | 1996-05-02 |
IL115663A (en) | 1999-08-17 |
RU2188015C2 (ru) | 2002-08-27 |
EP0785785A4 (en) | 1998-11-11 |
AU3895595A (en) | 1996-05-15 |
FI971635A0 (sv) | 1997-04-17 |
US5567714A (en) | 1996-10-22 |
CN1091598C (zh) | 2002-10-02 |
JPH10507757A (ja) | 1998-07-28 |
IL115663A0 (en) | 1996-01-19 |
EP0785785A1 (en) | 1997-07-30 |
CN1160998A (zh) | 1997-10-01 |
TW410156B (en) | 2000-11-01 |
US5504094A (en) | 1996-04-02 |
CZ115997A3 (en) | 1997-10-15 |
NZ295575A (en) | 2000-06-23 |
MY132056A (en) | 2007-09-28 |
NO971520D0 (no) | 1997-04-03 |
US5567715A (en) | 1996-10-22 |
AU689664B2 (en) | 1998-04-02 |
KR970706818A (ko) | 1997-12-01 |
US5576337A (en) | 1996-11-19 |
CZ287411B6 (en) | 2000-11-15 |
HUT76852A (en) | 1997-12-29 |
MX9702853A (es) | 1997-07-31 |
ZA958800B (en) | 1997-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO971520L (no) | Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y | |
NO944932D0 (no) | Hemming av trombin | |
NO973635L (no) | Fremgangsmåte for hemming av celle-celle adhesjon | |
IL111284A (en) | 2-phenyl-3-aroylbenzothiophenes for use as medicaments for inhibiting endometriosis | |
MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
NO944930D0 (no) | Hemming av dysfunksjonell uterin blödning | |
IL111289A (en) | 2-Phenyl-3- aroylbenzothiophenes for use as medicaments for inhibiting angiogenesis | |
DK0659411T3 (da) | Fremgangsmåde til forøgelse af libido hos kvinder efter menopausen | |
NO944929D0 (no) | Fremgangsmåte for å inhibere CNS-problemer i post-menopausale kvinner | |
NO944933L (no) | Fremgangsmåte for å inhibere sykdomstilstander i brystet | |
NO970786L (no) | Fremgangsmåte for hemming av benprotesedegradering | |
NO975580L (no) | Fremgangsmåte for å inhibere melanom | |
NO981578L (no) | FremgangsmÕte for hemming av plasminogenaktivatorhemmer I | |
NO971794L (no) | Fremgangsmåte for hemming av tilstander forbundet med bradykinin | |
NO973609L (no) | Fremgangsmåte for å inhibere effektene av IL-6 | |
NO971029L (no) | Fremgangsmåter for hemming av endometriale metoser | |
NO970783L (no) | Fremgangsmåte for å hindre endometrialkreft | |
MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
FI970716A (sv) | Förfaranden för förhindrande av primär endometrial hyperplasi | |
MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |